Brenda M. Gannon

Assistant Professor

UAMS

Also affiliated: University of Maryland, Baltimore (2024); National Institutes of Health (2016–2017); United States Department of Justice (2024); Drug Enforcement Administration (2024); National Institute on Drug Abuse (2016–2017); Mercer University (2020–2026); University of California, Los Angeles (2024); The University of Texas at San Antonio Health Science Center (2016–2022); Louisiana State University in Shreveport (2021); University of Arkansas Medical Center (2014–2016); Mercer University Health Sciences Center (2020–2021); National Institute on Alcohol Abuse and Alcoholism (2016–2017); South Texas Veterans Health Care System (2017); Louisiana State University Health Sciences Center Shreveport (2021)

17 h-index 55 pubs 953 cited

Research Areas

Biomedical Subjects

Links

ORCID Lab Website

OverviewAI-generated summary

Brenda M. Gannon's research investigates the pharmacological effects and reinforcing properties of synthetic cathinones, commonly known as 'bath salts.' Her work examines how these substances affect behavior, including drug discrimination, locomotor activity, and thermoregulation in animal models such as mice and rats. Gannon has explored the dose-response relationships and stereoselective effects of compounds like 3,4-methylenedioxypyrovalerone (MDPV) and α-pyrrolidinopentiophenone. Her studies also extend to the reinforcing effects of binary mixtures of bath salt constituents with other substances like caffeine. Gannon's research network includes collaborators from the University of Arkansas for Medical Sciences, with whom she has co-authored multiple publications. She has published 51 papers, accumulating 949 citations and an h-index of 17.

Metrics

h-index: 17
Publications: 55
Citations: 953

Positions

Assistant Professor 2021–present

University of Arkansas for Medical Sciences Pharmacology and Toxicology ORCID
Assistant Professor --Research Track 2020–2021

LSU Health Shreveport Phamacology, Toxicology, and Neuroscience ORCID
Research Assistant Professor 2019–2020

Mercer University College of Pharmacy Pharmaceutical Sciences ORCID
Laboratory Director 2018–2019

Steep Hill Arkansas ORCID
Postdoctoral Fellow 2015–2018

The University of Texas Health Science Center at San Antonio Pharmacology ORCID

Selected Publications

Direct comparison of the effects of functionally equivalent dosing regimens of methamphetamine, methcathinone, and α-pyrrolidinopropiophenone on behavioral and neurochemical markers of stimulant-induced neurotoxicity (2026)

Behavioural Pharmacology DOI OpenAlex
Interoceptive effects of N1-substituted lysergamides in rats: Role of agonist affinity at 5-hydroxytryptamine receptors and in vivo metabolism to lysergic acid diethylamide (2026)

Journal of Pharmacology and Experimental Therapeutics DOI OpenAlex
Behavioral and Pharmacokinetic Implications of Synthetic Cannabinoid Receptor Agonist and Benzodiazepine Co-Administration in C57BL/6 Mice (Abstract ID: 221452) (2026)

Journal of Pharmacology and Experimental Therapeutics DOI OpenAlex
Effects of Psychedelics Lysergic Acid Diethylamide and R (–)-2,5-Dimethoxy-4-Iodoamphetamine on Oral Opioid Consumption and Naloxone-Precipitated Withdrawal in Male C57Bl/6J Mice (2026)

Psychedelic Medicine DOI OpenAlex
Abuse potential assessment of novel central nervous system active and psychedelic substances for controlled substances act scheduling recommendations (2025)

Journal of Psychopharmacology 5 citations DOI OpenAlex
Effects of orally self-administered furanyl fentanyl and acryl fentanyl in mice: antinociception, dependence and withdrawal, and defense of consumption (2025)

Neuropharmacology 5 citations DOI OpenAlex
A “Furious” Effort to Develop Novel 3,4-Methylenedioxymethamphetamine-Like Therapeutics (2024)

Journal of Pharmacology and Experimental Therapeutics 1 citation DOI OpenAlex
Respiratory Depressant Effects of Fentanyl in Combination With Synthetic Cannabinoid Receptor Agonists: A Potential Mechanism for “Narcan-Resistant” Overdose (2024)

Drug and Alcohol Dependence DOI OpenAlex
The Development of Cannabinoids as Therapeutic Agents in the United States (2024)

Pharmacological Reviews 8 citations DOI OpenAlex
Erratum to “Effects of ambient temperature on locomotor activity and place conditioning elicited by abused psychostimulants in mice: Role of 3,4-methylenedioxy moiety” [Drug Alcohol Depend. 250 (2023) 110917] (2024)

Drug and Alcohol Dependence DOI OpenAlex
Phencyclidine-Like Abuse Liability and Psychosis-Like Neurocognitive Effects of Novel Arylcyclohexylamine Drugs of Abuse in Rodents (2024)

Journal of Pharmacology and Experimental Therapeutics 7 citations DOI OpenAlex
Structure-activity relationships for locomotor stimulant effects and monoamine transporter interactions of substituted amphetamines and cathinones (2023)

Neuropharmacology 9 citations DOI OpenAlex
Effects of ambient temperature on locomotor activity and place conditioning elicited by abused psychostimulants in mice: Role of 3,4-methylenedioxy moiety (2023)

Drug and Alcohol Dependence 1 citation DOI OpenAlex
Evaluation of morphine‐like effects of the mixed mu/delta agonist morphine‐6‐O‐sulfate in rats: Drug discrimination and physical dependence (2018)

Pharmacology Research & Perspectives 6 citations DOI OpenAlex
Role of monoaminergic systems and ambient temperature in bath salts constituent 3,4-methylenedioxypyrovalerone (MDPV)-elicited hyperthermia and locomotor stimulation in mice (2017)

Neuropharmacology 15 citations DOI OpenAlex